Skip to main content
OpenTrials
Completed

NCT Number: NCT05277948

Effect of Thumbtack Needle (TN) on Ovarian Reserve Function of Women With Diminished Ovarian Reserve (DOR)

Using a multi-center, large sample, randomized, patient-assessor blinded, sham-controlled clinical trial to evaluate the effect of thumbtack needle (TN) on ovarian function of patients with diminished ovarian reserve (DOR).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

About this study

Diminished ovarian reserve (DOR) is the precursor state of ovarian failure, and can cause the decline of women's reproductive function. Some studies have demonstrated that acupuncture can improve ovarian reserve function. Thumbtack needle (TN), as a kind of acupuncture, is a form of long-term indwelling intradermal needle therapy. TN has been found effective in treating DOR in our clinic. In this study, a multi-center, large sample, randomized, patient-assessor blinded, sham-controlled clinical trial was used to evaluate the effect of TN on ovarian reserve function of patients with diminished ovarian reserve (DOR).

First, patients will be recruited according to the inclusion criteria and exclusion criteria.

Second, baseline measurements (including ovarian reserve function, blood biochemical index, scores from the self-rating anxiety and depression scale, quality of life, sleep status) will be taken.

Third, each patient will receive the treatment of TN or sham TN for a total of 2 menstrual cycles.

Fourth, the above baseline measurements will be taken again as soon as the treatment is finished and outcome measures will be recorded after the treatment.

Last, Natural pregnancy outcomes includes natural pregnancy rate (including biochemical pregnancy rate, clinical pregnancy rate) and miscarriage rate during the treatment period and within 6 months after treatment completion will be followed up. Pregnancy outcome Includes number of oocytes retrieved, fertilization rate, embryo formation rate, blastocyst formation rate, biochemical pregnancy rate, clinical pregnancy rate and miscarriage rate during IVF-ET within 6 months after treatment completion will also be followed up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with age between 18 and 40 years;
  • Low ovarian reserve: AMH<1.1ng/ml; or AFC<7; or 10 U/L<FSH<25U/L or FSH/LH>3.6; or has a history of poor ovarian response, that is, in the last controlled hyperstimulation cycle, the number of retrieved oocytes<3. Any 2 of the above 4 conditions are met.
  • Sign informed consent voluntarily.

Exclusion criteria

  • Patient's chromosome is abnormal.
  • Patients with previous ovarian surgery because of such as ovarian teratoma or chocolate cyst and so on.
  • Patients with uncorrected endocrine disease, such as: Simple hyperthyroidism or hypothyroidism, hyperprolactinemia, insulin resistance, diabetes, adrenal diseases, etc.
  • Patients with definitively diagnosed autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, Sjogren's syndrome, Hashimoto's thyroiditis.
  • Patients with a history of cancer and has received radiotherapy or chemotherapy.
  • Patients had the treatment of acupuncture or thumbtack needle in recent 3 months.
  • Patients who take Chinese medicine decoction or granule during the treatment;
  • Patients unwilling to sign the informed consent of this study.

Treatment and study plan

active TN and ETN treatment

Other

The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight acupoints of CV4, CV3, SP6, ST36 and BL23 will be treated by disposable sterile thumbtack needle (TN) for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four acupoints of bilateral ovary acupoints and bilateral EX-B7 will be treated by disposable sterile electro-thumbtack needle (ETN) (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY) with pulsed electrical stimulation.

The patients will receive a treatment of 2 menstrual cycles.

sham TN and sham ETN treatment

Other

The acupoints used in the control group are the same as those in the treatment group. Eight points of CV4, CV3, SP6, ST36 and BL23 will be treated by the sterile sham thumbtack needle (TN) for single use (Hangzhou Zhuomai Medical Technology Co., LTD.), and four points of bilateral ovary acupoints and bilateral EX-B7 will be treated by disposable sterile sham electro-thumbtack needle (ETN) (Hangzhou Zhuomai Medical Technology Co., LTD.) with sham pulsed electrical stimulation.

The sham TN and ETN used in this group are identical in appearance, shape, and color to the active TN and ETN but lack the needle body, thus lacking the needle-penetrating effect. The stimulation method and frequency for the sham ETN are the same as those of the ETN group. The only difference is that the electrode pads used in the sham ETN group are specially designed as insulated controls.

The patients will receive a treatment of 2 menstrual cycles

Primary outcomes

  1. Evaluating the change of serum AMH level

    Time frame: 0 week and up to 4 weeks after treatment completion

    Assessing patients' serum level of AMH in ng/ml at baseline (0 week) and immediately (up to 4 weeks) after treatment completion.

  2. Evaluating the change of the ovarian antral follicle count (AFC)

    Time frame: 0 week and up to 4 weeks after treatment completion

    Counting the number of ovarian antral follicle count (AFC) on the second day of menstruation at baseline (0 week) and immediately (up to 4 weeks) after treatment completion.

Secondary outcomes

  1. Evaluating the serum levels of sex hormones

    Time frame: 0 week and up to 4 weeks after treatment completion

    Evaluating the serum levels of sex hormones (FSH, LH, E2, P, T, and PRL) on the second day of menstruation at baseline and immediately (up to 4 weeks) after treatment completion.

  2. Natural pregnancy outcomes include natural pregnancy rate and miscarriage rate

    Time frame: 0 week and within 6 months after treatment completion

    Natural pregnancy outcomes include natural pregnancy rate (including biochemical pregnancy rate, and clinical pregnancy rate) and miscarriage rate during the treatment period and within 6 months after treatment completion.

  3. Pregnancy outcomes of IVF-ET within 6 Months after Treatment Completion

    Time frame: 0 week and within 6 months after treatment completion

    Pregnancy outcomes Include number of oocytes retrieved, fertilization rate, embryo formation rate, blastocyst formation rate, biochemical pregnancy rate, clinical pregnancy rate, and miscarriage rate during IVF-ET within 6 months after treatment completion.

  4. Observing the level of transforming growth factor β (TGF β) in follicular fluid

    Time frame: within 6 months after treatment completion

    Observing follicular fluid level of transforming growth factor β (TGF β) when patients undergoing IVF/ICSI

    -ET after the treatment.

  5. Observing the level of tumor necrosis factor-α (TNF-α) in follicular fluid

    Time frame: within 6 months after treatment completion

    Observing follicular fluid level of TNF-α when patients undergoing IVF/ICSI

    -ET after the treatment.

  6. Observing the level of reactive oxygen species (ROS) in follicular fluid

    Time frame: within 6 months after treatment completion

    Observing follicular fluid level of ROS when patients undergoing IVF/ICSI

    -ET after the treatment.

  7. Observing the level of superoxide dismutase (SOD) in follicular fluid

    Time frame: within 6 months after treatment completion

    Observing follicular fluid level of SOD when patients undergoing IVF/ICSI

    -ET after the treatment.

  8. Blood corticotropin-releasing hormone (CRH) examination

    Time frame: 0 week and up to 4 weeks after treatment completion

    Observing the level of blood corticotropin-releasing hormone (CRH) at baseline and immediately after treatment

  9. Blood norepinephrine index examination

    Time frame: 0 week and up to 4 weeks after treatment completion

    Observing the level of blood norepinephrine at baseline and immediately after treatment

  10. Blood 5-hydroxytryptamine (5-HT) index examination

    Time frame: 0 week and up to 4 weeks after treatment completion

    Observing the level of blood 5-hydroxytryptamine (5-HT) at baseline and immediately after treatment

  11. Blood beta-aminobutyric acid (GABA) examination

    Time frame: 0 week and up to 4 weeks after treatment completion

    Observing the level of blood beta-aminobutyric acid (GABA) at baseline and immediately after treatment

  12. Blood dopamine (DA) examination

    Time frame: 0 week and up to 4 weeks after treatment completion

    Observing the level of blood dopamine (DA) at baseline and immediately after treatment

  13. Blood neuro-endorphin (β-ET) examination

    Time frame: 0 week and up to 4 weeks after treatment completion

    Observing the level of blood neuro-endorphin (β-ET) at baseline and immediately after treatment

  14. Evaluation of anxiety status

    Time frame: 0 week and up to 4 weeks after treatment completion

    Anxiety status will be assessed using Zung anxiety self-rating scale (Zung-SAS) at baseline and immediately after treatment.

  15. Evaluation of depression status

    Time frame: 0 week and up to 4 weeks after treatment completion

    Depression status will be assessed using Zung depression self-rating scale (Zung-SDS) at baseline and immediately after treatment.

  16. Evaluation of quality of life

    Time frame: 0 week and up to 4 weeks after treatment completion

    Quality of life will be assessed by SF-36 at baseline and immediately after treatment..

  17. Evaluation of sleep state

    Time frame: 0 week and up to 4 weeks after treatment completion

    Sleep status will be evaluated using Pittsburgh sleep quality index (PSQI) at baseline and immediately after treatment.

  18. Untargeted metabolomics levels in serum

    Time frame: 0 week and up to 4 weeks after treatment completion

    Untargeted metabolomics levels in patient serum before and after treatment.

  19. Untargeted metabolomics levels in follicular fluid

    Time frame: During IVF-ET within 6 months after study completion

    Observing untargeted metabolomics levels in follicular fluid collected from patients undergoing IVF/ICSI-ET cycle after treatment completion

  20. Proteomic analysis of granulosa cells

    Time frame: During IVF-ET within 6 months after study completion

    Proteomic analysis of granulosa cells collected during IVF-ET cycles after treatment.

Sponsors and collaborators

Lead sponsor

Dongmei Huang

Other

Registry information

Official study title

Effect of Thumbtack Needle (TN) on Ovarian Reserve Function of Women With Diminished Ovarian Reserve (DOR): A Randomized Controlled Clinical Trial

Acronym: TN-DOR

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Mar 14, 2022
Registry last updated
Feb 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.